We could not find any results for:
Make sure your spelling is correct or try broadening your search.
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MSCL Canada NewsWire TORONTO, le 17 déc. 2024 TORONTO, le 17 déc. 2024 /CNW/...
Canadian Investment Regulatory Organization Trade Resumption - MSCL Canada NewsWire TORONTO, Dec. 17, 2024 TORONTO, Dec. 17, 2024 /CNW/ - Trading resumes in: Company: Satellos Bioscience...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MSCL Canada NewsWire TORONTO, le 16 déc. 2024 TORONTO, le 16 déc. 2024 /CNW/...
Canadian Investment Regulatory Organization Trading Halt - MSCL Canada NewsWire TORONTO, Dec. 16, 2024 TORONTO, Dec. 16, 2024 /CNW/ - The following issues have been halted by CIRO: Company:...
- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult participants with genetically confirmed Duchenne...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -5.68181818182 | 0.88 | 0.89 | 0.78 | 138162 | 0.81608529 | CS |
4 | -0.06 | -6.74157303371 | 0.89 | 0.89 | 0.78 | 67281 | 0.83725446 | CS |
12 | -0.04 | -4.59770114943 | 0.87 | 1.32 | 0.67 | 142477 | 0.88175911 | CS |
26 | 0.335 | 67.6767676768 | 0.495 | 1.32 | 0.45 | 126818 | 0.7615439 | CS |
52 | 0.21 | 33.8709677419 | 0.62 | 1.32 | 0.38 | 95606 | 0.69461994 | CS |
156 | 0.21 | 33.8709677419 | 0.62 | 1.32 | 0.38 | 95606 | 0.69461994 | CS |
260 | 0.21 | 33.8709677419 | 0.62 | 1.32 | 0.38 | 95606 | 0.69461994 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions